Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Edmond G. Fita"'
Autor:
Keon-Joo, Lee, Dong Woo, Shin, Hong-Kyun, Park, Beom Joon, Kim, Jong-Moo, Park, Kyusik, Kang, Tai Hwan, Park, Kyung Bok, Lee, Keun-Sik, Hong, Yong-Jin, Cho, Dong-Eog, Kim, Wi-Sun, Ryu, Byung-Chul, Lee, Kyung-Ho, Yu, Mi-Sun, Oh, Soo Joo, Lee, Jae Guk, Kim, Jun, Lee, Jae-Kwan, Cha, Dae-Hyun, Kim, Joon-Tae, Kim, Kang-Ho, Choi, Jay Chol, Choi, Eva, Lesén, Jonatan, Hedberg, Amarjeet, Tank, Edmond G, Fita, Ji Eun, Song, Ji Sung, Lee, Juneyoung, Lee, Hee-Joon, Bae
Publikováno v:
Journal of Korean Medical Science. 37
This study aimed to present the prognosis after minor acute ischemic stroke (AIS) or transient ischemic attack (TIA), using a definition of subsequent stroke in accordance with recent clinical trials. In total, 9,506 patients with minor AIS (National
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db0318b5996c77dcfc5ff96cfbe17587
https://doi.org/10.3346/jkms.2022.37.e254
https://doi.org/10.3346/jkms.2022.37.e254
Autor:
Yashdeep Gupta, Tevfik Demir, K. Astamirova, A. Haggag, Athena Philis-Tsimikas, D. Roula, A.M. Nielsen, Edmond G. Fita, B.A. Bak
Publikováno v:
Diabetes Research and Clinical Practice. 147:157-165
Aims To confirm non-inferiority of insulin degludec/insulin aspart (IDegAsp) once-daily (OD) versus insulin glargine (IGlar) U100 OD + insulin aspart (IAsp) OD for HbA1c after 26 weeks, and compare efficacy and safety between groups at W26 + W38. Met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72f52bfbfbb00fccd2b0742bff706195
https://doi.org/10.1016/j.diabres.2018.10.024
https://doi.org/10.1016/j.diabres.2018.10.024
Publikováno v:
Diabetes Therapy
Introduction The majority of elderly patients (≥ 65 years of age) with type 2 diabetes mellitus (T2DM) will eventually require insulin therapy, but they are particularly vulnerable to hypoglycemia and challenging to treat. Insulin degludec/insulin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebd4c4301aa2b241f5441eacef3e9aa2
https://pubmed.ncbi.nlm.nih.gov/30474818
https://pubmed.ncbi.nlm.nih.gov/30474818
Publikováno v:
Clinical Pharmacokinetics
Insulin degludec/insulin aspart (IDegAsp; 70 % IDeg and 30 % IAsp) is a soluble combination of two individual insulin analogues in one product, designed to provide mealtime glycaemic control due to the IAsp component and basal glucose-lowering effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17ae7c10a5274bfca47d17ac95e16954
Autor:
Fulcher, Greg1 greg.fulcher@sydney.edu.au, Mehta, Roopa2, Fita, Edmond G.3, Ekelund, Magnus3, Bain, Stephen C.4
Publikováno v:
Diabetes Therapy. Feb2019, Vol. 10 Issue 1, p107-118. 12p.
Publikováno v:
Clinical Pharmacokinetics; Apr2017, Vol. 56 Issue 4, p339-354, 16p